Search
Skip to Search Results-
Fall 2019
Targeting a single pathway is not enough to treat cancer because of compensatory mechanisms against anticancer therapy via alternative molecular pathways for survival and proliferation of malignant cells. Given the unacceptable toxicity associated with conventional therapy, nucleic acids such as...
-
Spring 2022
Small interfering ribonucleic acids (siRNA) effectively downregulate the specific gene expression from cleaving the associated messenger RNA (mRNA) in the cytoplasm, which is a promising strategy in cancer management as one of the origins of cancer is the unregulated expression of the oncogene....
-
Safe Polymeric Nucleic Acid Delivery Systems for Cancer Therapy: Focus on Breast Cancer and Chronic Myeloid Leukemia
DownloadFall 2021
Meenakshi Sundaram, Daniel Nisakar
RNA interference (RNAi) is a promising technology to specifically target the upregulated genes that provide uncontrolled proliferation and survival of cancers. The target specific silencing is accomplished by the delivery of small interfering RNA (siRNA), which require safe delivery systems to...
-
Spring 2017
BCR-ABL fusion oncogene is the main driver mutation of Chronic Myeloid Leukemia (CML) that controls initiation, maintenance and progression to more aggressive stages of the disease. Current therapies with tyrosine kinase inhibitors in CML involve certain limitations, such as drug resistance and...